PT-141 (Bremelanotide): What the Evidence Actually Shows

Grade A, human RCT evidence FDA-approved (specific indication)

The short version

A melanocortin receptor agonist. Acts on central nervous system pathways, not blood flow, mechanistically unlike PDE5 inhibitors.
FDA-approved June 21, 2019 as Vyleesi for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
Two Phase 3 RECONNECT trials, over 1,200 women.
Nausea affected 40% versus 1% on placebo. 13% discontinued because of it.
Approximately 1% developed focal hyperpigmentation, not always reversible.

What it is

Bremelanotide is a synthetic melanocortin receptor agonist. It works on central pathways in the brain involved in sexual desire rather than on peripheral vascular mechanisms. That's a genuinely different target from the more familiar PDE5 inhibitors, which act on blood flow, and it's why it's dosed situationally rather than daily.

What the research shows

FDA approval was supported primarily by the two Phase 3 RECONNECT trials, plus integrated safety data from the wider development program, Phase 3 randomized controlled data in over 1,200 women.^[1]

This is one of the few compounds in this whole category where "clinically proven" is a defensible phrase rather than marketing.

The side effect profile, read this part properly

Adverse events occurred in 76.6% of the bremelanotide arm versus 58.2% on placebo. The difference was driven almost entirely by expected pharmacological effects:^[1]

Nausea, 40% versus 1% on placebo. About 8% needed antiemetic treatment. 13% discontinued the drug because of it.
Flushing, 20%
Injection site reactions, 13%
Headache, 11%
Focal hyperpigmentation, about 1%, typically on the face, gums, or breasts. Reversible in most cases over weeks to months, but not always.

We're stating this in full because roughly one in eight trial participants stopped taking it over nausea. That is a real thing to know before you start, not after.

Who it may suit

Premenopausal women with acquired, generalized HSDD, the approved indication
People for whom desire rather than physical function is the primary issue
People who have had other causes worked up first

Male use is off-label with a materially different and thinner evidence base. Our assessment routes differently by sex for exactly this reason.

Who should not use this

Uncontrolled hypertension or known cardiovascular disease, transient blood pressure increases are an expected effect
Pregnancy or breastfeeding
People with significant risk factors where transient BP elevation is unacceptable

The Vyleesi label limits use to 8 doses per 28 days and discourages more than one dose in 24 hours. Those limits exist for reasons.

What this will not do

It will not fix a relationship or psychological cause. HSDD frequently has contributors this doesn't touch.
It will not resolve an underlying vascular or hormonal condition that hasn't been worked up.
It will not work like a PDE5 inhibitor. Different mechanism, different target, different expectations.
It is not a daily medication. Situational dosing, with a monthly ceiling.

How it's administered

Subcutaneous autoinjector, taken at least 45 minutes before anticipated sexual activity, per the Vyleesi label.

We do not publish dosing guidance. The figures above are what the approved label specifies in a clinical setting. They are reported here as regulatory fact, not as instructions.

Regulatory status

FDA-approved as Vyleesi for acquired, generalized HSDD in premenopausal women. Any other use, including any use in men, is off-label. Bremelanotide is under patent as a branded product.

Common questions

Is the nausea really that common?

Yes. 40% versus 1% on placebo, and 13% of trial participants discontinued over it. Some people find it manageable or transient; many don't. The trial protocols and the approved label both address antiemetic strategy, and that is where the published figures come from.

What about the skin darkening?

About 1% of participants developed focal hyperpigmentation, usually on the face, gums, or breasts. It resolved over weeks to months in most cases but not all. Risk appears related to frequency of use, which is part of why the label caps monthly doses.

Does it work for men?

Off-label, with a substantially thinner evidence base than the female HSDD indication. The published male data is small, and the gap between it and the approved indication is much larger than the marketing suggests.

References

Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstetrics & Gynecology2019. Link

See if this fits your goals